Abstract:The rapid development of a stereoselective route for CXCR7 antagonist ACT-1004-1239 was needed, as the large-scale chromatographic separation of enantiomers was not a viable option for a resupply campaign that targeted >30 kg of API. The key to success was the stereoselective reduction of a chiral enamine derived from inexpensive (S)-α-methylbenzylamine. The reduction showed good selectivity for the desired cis-3R,4S-isomer, and the pure diastereomer (d.r. >98:2) was isolated as its TFA salt. After removal of the ethylbenzyl group and amide coupling with 5-(2,4-difluorophenyl)isoxazole-3-carboxylic acid, the enantiopure cis-3R,4S-amide was isolated. The subsequent epimerization of the 3-position adjacent to the methyl ester turned out to be a formidable challenge, as the standard conditions with NaOMe led to the formation of a thermodynamic mixture of the cis and trans isomers (final ratio of ∼1:4). Therefore, a new procedure was developed in which the methyl ester was transesterified in situ to the isopropyl ester with KOiPr in iPrOH, followed by epimerization to the trans-iPr-ester (final cis:trans ratio 5:95). After saponification with aqueous KOH, the desired trans-3S,4S-acid was isolated in overall 76% yield. After amide coupling and Boc deprotection, the final reductive amination with cyclopropanecarboxaldehyde was also vastly improved. A novel NaBH(OAc)3 solution in DMSO was used for the reaction and cleanly provided the API with high purity after simple aqueous quench without the need for any solvent switches or aqueous workups. As a proof of concept, 240 g of API was produced in house with the novel stereoselective route, which was then also used to produce over 30 kg of GMP material at an external manufacturer for Phase 2 clinical studies.

Efficient and Scalable Process for the Synthesis of Antihypercholesterolemic Drug Ezetimibe

New Synthesis Process for the Synthesis of Ezetimibe

Synthesis and Chiral Resolution of 2,2- Dimethylcyclopropane Carboxylic Acid

Synthesis of a New Antihyperlipidaemic Agent-Simvastatin

Redesign of a Short-Chain Dehydrogenase/reductase for Asymmetric Synthesis of Ethyl (R)-2-hydroxy-4-phenylbutanoate Based on Per-Residue Free Energy Decomposition and Sequence Conservatism Analysis

Improved Enantioselectivity of E. Coli BioH in Kinetic Resolution of Methyl (S)-3-cyclohexene-1-carboxylate by Combinatorial Modulation of Steric and Aromatic Interactions

Biocatalytic Stereoselective Synthesis of Chiral Precursors for Liposoluble β1 Receptor Blocker Nebivolol

An Improved Process for Chiron Synthesis of the Atorvastatin Side Chain

Building a Quaternary Stereogenic Center on Dihydroazaindole Carboxylic Acid through Scalable Process Development

Enantio‐ and Diastereoselective Synthesis of Chiral Syn ‐Aryl β‐Hydroxy α‐Amino Esters via Biocatalytic Dynamic Reductive Kinetic Resolution

Development of a Practical, Biocatalytic Synthesis of Tert-Butyl (R)-3-hydroxyl-5-hexenoate: A Key Intermediate to the Statin Side Chain

Scalable Synthesis of Antihistamines and Sensipar via Intensified Hydrogen Borrowing Methodology

Highly efficient synthesis of the chiral ACE inhibitor intermediate (R)-2-hydroxy-4-phenylbutyrate ethyl ester via engineered bi-enzyme coupled systems

Chemo-enzymatic Asymmetric Synthesis of S-citalopram by Lipase-Catalyzed Cyclic Resolution and Stereoinversion of Quaternary Stereogenic Center.

Facile Entry to an Efficient and Practical Enantioselective Synthesis of A Polycyclic Cholesteryl Ester Transfer Protein Inhibitor

A Three‐Step Chemoenzymatic Cascade Synthesis of Miconazole Analogues Based on the Asymmetric Synthesis of β‐Heteroaryl Amino Alcohols via Ketoreductases

Sustainable Asymmetric Synthesis of Diltiazem Precursor Enabled by Recombinant Escherichia coli Whole Cells Co‐Expressing an Engineered Ketoreductase and Glucose Dehydrogenase

Direct Differentiation of Stereoisomers of Ezetimibe/ambrisentan/atorvastatin and Their Mechanism Study by Electrospray Ionization Quadrupole Time-of-flight Mass Spectrometry

Development of a Scalable, Stereoselective Second-Generation Route for CXCR7 Antagonist ACT-1004-1239 via Chiral Enamine Reduction and a Novel Telescoped Sequence of Transesterification, cis -to- trans Epimerization, and Saponification

Highly efficient synthesis of rosuvastatin intermediate using a carbonyl reductase–cofactor co‐immobilized biocatalyst in the non‐aqueous biosystem

Development of a Cost-Efficient Process Toward a Key Synthetic Intermediate of the EZH2 Inhibitor PF-06821497